The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus.
The effect of cannabinoids on motion-induced emesis is unknown. The present study investigated the action of phytocannabinoids against motion-induced emesis in Suncus murinus. Suncus murinus were injected intraperitoneally with either cannabidiol (CBD) (0.5, 1, 2, 5, 10, 20 and 40 mg/kg), Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 0.5, 3, 5 and 10 mg/kg) or vehicle 45 min. before exposure to a 10-min. horizontal motion stimulus (amplitude 40 mm, frequency 1 Hz). In further investigations, the CB(1) receptor antagonist, N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM 251; 5 mg/kg), was injected 15 min. prior to an injection of Delta(9)-THC (3 mg/kg). The motion stimulus was applied 45 min. later. The number of emetic episodes and latency of onset to the first emetic episode were recorded. Pre-treatment with the above doses of CBD did not modify the emetic response to the motion stimulus as compared to the vehicle-treated controls. Application of the higher doses of Delta(9)-THC induced emesis in its own right, which was inhibited by AM 251. Furthermore, pre-treatment with Delta(9)-THC dose-dependently attenuated motion-induced emesis, an effect that was inhibited by AM 251. AM 251 neither induced an emetic response nor modified motion-induced emesis. The present study indicates that Delta(9)-THC, acting via the CB(1) receptors, is anti-emetic to motion, and that CBD has no effect on motion-induced emesis in Suncus murinus.
Cluny
Nina L
NL
The School of Pharmacy, University of Bradford, Bradford, West Yorkshire, UK. ncluny@ucalgary.ca
Naylor
Robert J
RJ
Whittle
Brian A
BA
Javid
Farideh A
FA
D000818:Animals; D000932:Antiemetics / Q000494:pharmacology / Q000627:therapeutic use*; D002185:Cannabidiol / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D013759:Dronabinol / Q000494:pharmacology / Q000627:therapeutic use*; D009041:Motion Sickness / Q000150:complications / Q000378:metabolism / Q000517:prevention & control*; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism; D012788:Shrews; D014722:Vestibule, Labyrinth / Q000187:drug effects; D014839:Vomiting / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*
D000932:Antiemetics; D043884:Receptor, Cannabinoid, CB1; D002185:Cannabidiol; D013759:Dronabinol